Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
about
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoPhase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsApproaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesPeptides as targeting probes against tumor vasculature for diagnosis and drug deliveryTargeting the tumor vasculature to enhance T cell activityRecombinant IFN-α2a-NGR exhibits higher inhibitory function on tumor neovessels formation compared with IFN-α2a in vivo and in vitroThe X-ray Crystal Structure of Human Aminopeptidase N Reveals a Novel Dimer and the Basis for Peptide ProcessingHuman Lipocalin-Type Prostaglandin D Synthase-Based Drug Delivery System for Poorly Water-Soluble Anti-Cancer Drug SN-38NGR-peptide-drug conjugates with dual targeting properties.Specialization of tumour vasculature.Targeting the prostate for destruction through a vascular address.Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature.Combinatorial peptide libraries: mining for cell-binding peptides.Therapeutic cancer targeting peptides.Drug identification through in vivo screening of chemical libraries.Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis.Display technologies: application for the discovery of drug and gene delivery agents.Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Combinatorial ligand-directed lung targeting.Potential of phage-displayed peptide library technology to identify functional targeting peptidesEvaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma.Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome.Dual-targeted peptide-conjugated multifunctional fluorescent probe with AIEgen for efficient nucleus-specific imaging and long-term tracing of cancer cellsImmunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.Aminopeptidase N (CD13) as a target for cancer chemotherapy.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.Identification of tissue-specific targeting peptide.Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.Cancer-associated CD43 glycoforms as target of immunotherapy.Intratumoral drug delivery with nanoparticulate carriers.Novel therapies in phase II and III trials for malignant pleural mesothelioma.Bacteriophages and medical oncology: targeted gene therapy of cancer.Systemic use of tumor necrosis factor alpha as an anticancer agentImpaired angiogenesis in aminopeptidase N-null mice.Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironmentProgress report on the potential of angiogenesis inhibitors for neuro-oncology.Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy.
P2860
Q24530544-C46D0C32-6D34-4129-8E47-5CB7B9209004Q24633820-7CBBA033-14FC-43B8-8E3E-4F1406C1E162Q26852287-659C8F86-D79A-48E2-A656-C26FA7B40514Q26991991-EFBD93C8-A89C-4059-AAED-CDAAA60130A2Q27024850-3740E296-2591-46DA-9FCC-B59AD8944896Q27026329-286E21D8-E06C-4E77-84C1-8C4BF0638EAFQ27316848-315EBF4B-059F-4E59-8788-030F58E72F6AQ27671790-D0760EBC-5C5C-45E2-BAED-6AB41F81451CQ28550622-6B6A94A0-208B-4185-9E1F-8CB6C9820F32Q30354486-CAAF772D-E960-44AC-A221-8A5AFF3D1AD5Q30896811-0017A4C9-5013-436E-A8F8-09A5BD0A3F8EQ31037658-AFBE5019-8E9C-4636-B2F0-88D6EE20D063Q31039259-32FAE2E8-C99C-4D1D-B94F-79CF40571C3FQ31144876-44AA8566-BD45-4497-BEEE-89CCA7B29418Q33184888-BC6E213A-E04C-44ED-8A61-F057DF2BE907Q33203372-DE269C24-F368-4DFA-945A-E7D3E470F797Q33225648-84481367-CD52-4E8A-AD76-BA151494D797Q33264491-7D3CF345-7582-4861-ABE9-E95344D5D5C9Q33325343-96FC0281-330D-4EF7-8CE7-7B4595CD2A05Q33494276-99FE628A-BC05-4C6A-9CE7-6510A2551BF8Q33530848-BD7DB05F-A21E-4A30-A458-5C1229C65024Q33607479-B7873E19-114D-4ED1-A8CF-0F8F238C7C0DQ33762115-1E9E8C62-D134-4C24-8C7C-9EA993CA6E94Q33800277-BBA46713-1115-458C-9580-70EFA45E7C91Q33960866-7CDC474D-0F21-4ED0-BC3C-15C3247FC765Q34157418-36B156D2-AD89-4638-85F0-32101971DD78Q34253748-52B4B13F-163D-4018-B6F1-F7E44BC497B8Q34271190-285E9129-CDF5-4A99-A7DC-48E9F4D4D697Q34458951-754F0CB0-B023-4463-892F-D9CE9311196EQ34730638-B973FF7C-517F-44E2-8732-1ED6DA6BDFB4Q35072238-9AF571F9-CFCE-4C1E-B68C-E53E1338589BQ35091415-CBA457DC-5DA8-4850-B092-74524E248468Q35129535-C547BC9C-8C81-4346-8FB8-70AE6DDDDCF3Q35204972-91FF08F8-9B84-437D-A09F-467D464098F8Q35640180-33FC1355-D66F-407E-90C5-9A5565F58390Q35670097-C38A1248-7B3A-4C41-AD28-6325A4FAE902Q35681062-839F27BE-0D79-48B2-86FE-26F7BF2DC851Q35749834-A57FDC82-DA68-4F0C-B0CA-52655517DC42Q35964419-73975419-045C-4198-8213-F1071FBE5BBBQ35974293-2A883C51-DB9F-44C8-A9A9-B6200EBCF3BA
P2860
Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Enhancement of tumor necrosis ...... ry to aminopeptidase N (CD13).
@en
type
label
Enhancement of tumor necrosis ...... ry to aminopeptidase N (CD13).
@en
prefLabel
Enhancement of tumor necrosis ...... ry to aminopeptidase N (CD13).
@en
P2093
P50
P356
P1433
P1476
Enhancement of tumor necrosis ...... ry to aminopeptidase N (CD13).
@en
P2093
P2888
P304
P356
10.1038/81183
P577
2000-11-01T00:00:00Z
P5875
P6179
1004929050